Epibase^® assists life science companies by immunoprofiling there therapeutic protein leads at research level and throughout the drug development cycle.

Compare the immunogenicity of drug leads
Epibase^® profiles allow you to identify those leads that show the lowest immunogenicity.

Optimize your protein leads
Putative T-cell epitopes can be discovered at research level.
This platform also assists you in selecting the mutations/variants needed to reduce immunogenicity.

Focus on HLA subtypes that are disease specific
In specific cases, HLA alleles are linked with diseases.
Epibase^® allows exploring if the drug candidates are safe for the targeted patient population.

Document the immunogenicity in regulatory filings
What is the expected T-cell driven immunogenicity of the drug lead?